Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome
Trial details
- Registry ID
- NCT02311673
- Phase
- Phase 2
The FDA approved Setmelanotide (IMCIVREE) on 25 Nov 2020.
Drug identity checked against registry records
Also recorded as IMCIVREE; Imcivree; RM-493; SET
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2020-11-25Day | Setmelanotide | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA213793", "applicant_as_listed_by_fda": "RHYTHM", "brand_names": ["IMCIVREE"], "active_ingredients": ["SETMELANOTIDE ACETATE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20201125", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |